Global Cancer Minimal Residual Disease Testing Market Research Report 2024(Status and Outlook)
Report Overview
Minimal residual disease (MRD) isa term used to describe the small number of cancer cells in the body after cancer treatment. An MRD positive test result means that disease was still detected after treatment. An MRD negative result means that no disease was detected after treatment.
This report provides a deep insight into the global Cancer Minimal Residual Disease Testing market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Cancer Minimal Residual Disease Testing Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Cancer Minimal Residual Disease Testing market in any manner.
Global Cancer Minimal Residual Disease Testing Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Adaptive Biotechnologies Corporation
ArcherDX, Inc. (Invitae Corporation)
Asuragen
Arup Laboratories
Bio-Rad Laboratories
Cergentis B.V.
F. Hoffmann- La Roche Ltd
Guardant Health
ICON plc
Invivoscribe
Laboratory Corporation of America Holdings
Mission Bio
Natera, Inc.
NeoGenomics Laboratories
Opko Health
Quest Diagnostics Incorporated
Sysmex Corporation
Genetron Health
Market Segmentation (by Type)
Flow Cytometry
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Other
Market Segmentation (by Application)
Hematological Malignancies
Leukemia
Lymphoma
Solid Tumors
Other
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Cancer Minimal Residual Disease Testing Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
Minimal residual disease (MRD) isa term used to describe the small number of cancer cells in the body after cancer treatment. An MRD positive test result means that disease was still detected after treatment. An MRD negative result means that no disease was detected after treatment.
This report provides a deep insight into the global Cancer Minimal Residual Disease Testing market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Cancer Minimal Residual Disease Testing Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Cancer Minimal Residual Disease Testing market in any manner.
Global Cancer Minimal Residual Disease Testing Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Adaptive Biotechnologies Corporation
ArcherDX, Inc. (Invitae Corporation)
Asuragen
Arup Laboratories
Bio-Rad Laboratories
Cergentis B.V.
F. Hoffmann- La Roche Ltd
Guardant Health
ICON plc
Invivoscribe
Laboratory Corporation of America Holdings
Mission Bio
Natera, Inc.
NeoGenomics Laboratories
Opko Health
Quest Diagnostics Incorporated
Sysmex Corporation
Genetron Health
Market Segmentation (by Type)
Flow Cytometry
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Other
Market Segmentation (by Application)
Hematological Malignancies
Leukemia
Lymphoma
Solid Tumors
Other
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Cancer Minimal Residual Disease Testing Market
- Overview of the regional outlook of the Cancer Minimal Residual Disease Testing Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Cancer Minimal Residual Disease Testing Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Cancer Minimal Residual Disease Testing
1.2 Key Market Segments
1.2.1 Cancer Minimal Residual Disease Testing Segment by Type
1.2.2 Cancer Minimal Residual Disease Testing Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 CANCER MINIMAL RESIDUAL DISEASE TESTING MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Cancer Minimal Residual Disease Testing Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Cancer Minimal Residual Disease Testing Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 CANCER MINIMAL RESIDUAL DISEASE TESTING MARKET COMPETITIVE LANDSCAPE
3.1 Global Cancer Minimal Residual Disease Testing Sales by Manufacturers (2019-2024)
3.2 Global Cancer Minimal Residual Disease Testing Revenue Market Share by Manufacturers (2019-2024)
3.3 Cancer Minimal Residual Disease Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Cancer Minimal Residual Disease Testing Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Cancer Minimal Residual Disease Testing Sales Sites, Area Served, Product Type
3.6 Cancer Minimal Residual Disease Testing Market Competitive Situation and Trends
3.6.1 Cancer Minimal Residual Disease Testing Market Concentration Rate
3.6.2 Global 5 and 10 Largest Cancer Minimal Residual Disease Testing Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 CANCER MINIMAL RESIDUAL DISEASE TESTING INDUSTRY CHAIN ANALYSIS
4.1 Cancer Minimal Residual Disease Testing Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF CANCER MINIMAL RESIDUAL DISEASE TESTING MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 CANCER MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Cancer Minimal Residual Disease Testing Sales Market Share by Type (2019-2024)
6.3 Global Cancer Minimal Residual Disease Testing Market Size Market Share by Type (2019-2024)
6.4 Global Cancer Minimal Residual Disease Testing Price by Type (2019-2024)
7 CANCER MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Cancer Minimal Residual Disease Testing Market Sales by Application (2019-2024)
7.3 Global Cancer Minimal Residual Disease Testing Market Size (M USD) by Application (2019-2024)
7.4 Global Cancer Minimal Residual Disease Testing Sales Growth Rate by Application (2019-2024)
8 CANCER MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION BY REGION
8.1 Global Cancer Minimal Residual Disease Testing Sales by Region
8.1.1 Global Cancer Minimal Residual Disease Testing Sales by Region
8.1.2 Global Cancer Minimal Residual Disease Testing Sales Market Share by Region
8.2 North America
8.2.1 North America Cancer Minimal Residual Disease Testing Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Cancer Minimal Residual Disease Testing Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Cancer Minimal Residual Disease Testing Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Cancer Minimal Residual Disease Testing Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Cancer Minimal Residual Disease Testing Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Adaptive Biotechnologies Corporation
9.1.1 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Basic Information
9.1.2 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Product Overview
9.1.3 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Product Market Performance
9.1.4 Adaptive Biotechnologies Corporation Business Overview
9.1.5 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing SWOT Analysis
9.1.6 Adaptive Biotechnologies Corporation Recent Developments
9.2 ArcherDX, Inc. (Invitae Corporation)
9.2.1 ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Basic Information
9.2.2 ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Product Overview
9.2.3 ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Product Market Performance
9.2.4 ArcherDX, Inc. (Invitae Corporation) Business Overview
9.2.5 ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing SWOT Analysis
9.2.6 ArcherDX, Inc. (Invitae Corporation) Recent Developments
9.3 Asuragen
9.3.1 Asuragen Cancer Minimal Residual Disease Testing Basic Information
9.3.2 Asuragen Cancer Minimal Residual Disease Testing Product Overview
9.3.3 Asuragen Cancer Minimal Residual Disease Testing Product Market Performance
9.3.4 Asuragen Cancer Minimal Residual Disease Testing SWOT Analysis
9.3.5 Asuragen Business Overview
9.3.6 Asuragen Recent Developments
9.4 Arup Laboratories
9.4.1 Arup Laboratories Cancer Minimal Residual Disease Testing Basic Information
9.4.2 Arup Laboratories Cancer Minimal Residual Disease Testing Product Overview
9.4.3 Arup Laboratories Cancer Minimal Residual Disease Testing Product Market Performance
9.4.4 Arup Laboratories Business Overview
9.4.5 Arup Laboratories Recent Developments
9.5 Bio-Rad Laboratories
9.5.1 Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Basic Information
9.5.2 Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Product Overview
9.5.3 Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Product Market Performance
9.5.4 Bio-Rad Laboratories Business Overview
9.5.5 Bio-Rad Laboratories Recent Developments
9.6 Cergentis B.V.
9.6.1 Cergentis B.V. Cancer Minimal Residual Disease Testing Basic Information
9.6.2 Cergentis B.V. Cancer Minimal Residual Disease Testing Product Overview
9.6.3 Cergentis B.V. Cancer Minimal Residual Disease Testing Product Market Performance
9.6.4 Cergentis B.V. Business Overview
9.6.5 Cergentis B.V. Recent Developments
9.7 F. Hoffmann- La Roche Ltd
9.7.1 F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Basic Information
9.7.2 F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Product Overview
9.7.3 F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Product Market Performance
9.7.4 F. Hoffmann- La Roche Ltd Business Overview
9.7.5 F. Hoffmann- La Roche Ltd Recent Developments
9.8 Guardant Health
9.8.1 Guardant Health Cancer Minimal Residual Disease Testing Basic Information
9.8.2 Guardant Health Cancer Minimal Residual Disease Testing Product Overview
9.8.3 Guardant Health Cancer Minimal Residual Disease Testing Product Market Performance
9.8.4 Guardant Health Business Overview
9.8.5 Guardant Health Recent Developments
9.9 ICON plc
9.9.1 ICON plc Cancer Minimal Residual Disease Testing Basic Information
9.9.2 ICON plc Cancer Minimal Residual Disease Testing Product Overview
9.9.3 ICON plc Cancer Minimal Residual Disease Testing Product Market Performance
9.9.4 ICON plc Business Overview
9.9.5 ICON plc Recent Developments
9.10 Invivoscribe
9.10.1 Invivoscribe Cancer Minimal Residual Disease Testing Basic Information
9.10.2 Invivoscribe Cancer Minimal Residual Disease Testing Product Overview
9.10.3 Invivoscribe Cancer Minimal Residual Disease Testing Product Market Performance
9.10.4 Invivoscribe Business Overview
9.10.5 Invivoscribe Recent Developments
9.11 Laboratory Corporation of America Holdings
9.11.1 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Basic Information
9.11.2 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Product Overview
9.11.3 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Product Market Performance
9.11.4 Laboratory Corporation of America Holdings Business Overview
9.11.5 Laboratory Corporation of America Holdings Recent Developments
9.12 Mission Bio
9.12.1 Mission Bio Cancer Minimal Residual Disease Testing Basic Information
9.12.2 Mission Bio Cancer Minimal Residual Disease Testing Product Overview
9.12.3 Mission Bio Cancer Minimal Residual Disease Testing Product Market Performance
9.12.4 Mission Bio Business Overview
9.12.5 Mission Bio Recent Developments
9.13 Natera, Inc.
9.13.1 Natera, Inc. Cancer Minimal Residual Disease Testing Basic Information
9.13.2 Natera, Inc. Cancer Minimal Residual Disease Testing Product Overview
9.13.3 Natera, Inc. Cancer Minimal Residual Disease Testing Product Market Performance
9.13.4 Natera, Inc. Business Overview
9.13.5 Natera, Inc. Recent Developments
9.14 NeoGenomics Laboratories
9.14.1 NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Basic Information
9.14.2 NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Product Overview
9.14.3 NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Product Market Performance
9.14.4 NeoGenomics Laboratories Business Overview
9.14.5 NeoGenomics Laboratories Recent Developments
9.15 Opko Health
9.15.1 Opko Health Cancer Minimal Residual Disease Testing Basic Information
9.15.2 Opko Health Cancer Minimal Residual Disease Testing Product Overview
9.15.3 Opko Health Cancer Minimal Residual Disease Testing Product Market Performance
9.15.4 Opko Health Business Overview
9.15.5 Opko Health Recent Developments
9.16 Quest Diagnostics Incorporated
9.16.1 Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Basic Information
9.16.2 Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Product Overview
9.16.3 Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Product Market Performance
9.16.4 Quest Diagnostics Incorporated Business Overview
9.16.5 Quest Diagnostics Incorporated Recent Developments
9.17 Sysmex Corporation
9.17.1 Sysmex Corporation Cancer Minimal Residual Disease Testing Basic Information
9.17.2 Sysmex Corporation Cancer Minimal Residual Disease Testing Product Overview
9.17.3 Sysmex Corporation Cancer Minimal Residual Disease Testing Product Market Performance
9.17.4 Sysmex Corporation Business Overview
9.17.5 Sysmex Corporation Recent Developments
9.18 Genetron Health
9.18.1 Genetron Health Cancer Minimal Residual Disease Testing Basic Information
9.18.2 Genetron Health Cancer Minimal Residual Disease Testing Product Overview
9.18.3 Genetron Health Cancer Minimal Residual Disease Testing Product Market Performance
9.18.4 Genetron Health Business Overview
9.18.5 Genetron Health Recent Developments
10 CANCER MINIMAL RESIDUAL DISEASE TESTING MARKET FORECAST BY REGION
10.1 Global Cancer Minimal Residual Disease Testing Market Size Forecast
10.2 Global Cancer Minimal Residual Disease Testing Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Cancer Minimal Residual Disease Testing Market Size Forecast by Country
10.2.3 Asia Pacific Cancer Minimal Residual Disease Testing Market Size Forecast by Region
10.2.4 South America Cancer Minimal Residual Disease Testing Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Cancer Minimal Residual Disease Testing by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Cancer Minimal Residual Disease Testing Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Cancer Minimal Residual Disease Testing by Type (2025-2030)
11.1.2 Global Cancer Minimal Residual Disease Testing Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Cancer Minimal Residual Disease Testing by Type (2025-2030)
11.2 Global Cancer Minimal Residual Disease Testing Market Forecast by Application (2025-2030)
11.2.1 Global Cancer Minimal Residual Disease Testing Sales (K Units) Forecast by Application
11.2.2 Global Cancer Minimal Residual Disease Testing Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Cancer Minimal Residual Disease Testing
1.2 Key Market Segments
1.2.1 Cancer Minimal Residual Disease Testing Segment by Type
1.2.2 Cancer Minimal Residual Disease Testing Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 CANCER MINIMAL RESIDUAL DISEASE TESTING MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Cancer Minimal Residual Disease Testing Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Cancer Minimal Residual Disease Testing Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 CANCER MINIMAL RESIDUAL DISEASE TESTING MARKET COMPETITIVE LANDSCAPE
3.1 Global Cancer Minimal Residual Disease Testing Sales by Manufacturers (2019-2024)
3.2 Global Cancer Minimal Residual Disease Testing Revenue Market Share by Manufacturers (2019-2024)
3.3 Cancer Minimal Residual Disease Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Cancer Minimal Residual Disease Testing Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Cancer Minimal Residual Disease Testing Sales Sites, Area Served, Product Type
3.6 Cancer Minimal Residual Disease Testing Market Competitive Situation and Trends
3.6.1 Cancer Minimal Residual Disease Testing Market Concentration Rate
3.6.2 Global 5 and 10 Largest Cancer Minimal Residual Disease Testing Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 CANCER MINIMAL RESIDUAL DISEASE TESTING INDUSTRY CHAIN ANALYSIS
4.1 Cancer Minimal Residual Disease Testing Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF CANCER MINIMAL RESIDUAL DISEASE TESTING MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 CANCER MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Cancer Minimal Residual Disease Testing Sales Market Share by Type (2019-2024)
6.3 Global Cancer Minimal Residual Disease Testing Market Size Market Share by Type (2019-2024)
6.4 Global Cancer Minimal Residual Disease Testing Price by Type (2019-2024)
7 CANCER MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Cancer Minimal Residual Disease Testing Market Sales by Application (2019-2024)
7.3 Global Cancer Minimal Residual Disease Testing Market Size (M USD) by Application (2019-2024)
7.4 Global Cancer Minimal Residual Disease Testing Sales Growth Rate by Application (2019-2024)
8 CANCER MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION BY REGION
8.1 Global Cancer Minimal Residual Disease Testing Sales by Region
8.1.1 Global Cancer Minimal Residual Disease Testing Sales by Region
8.1.2 Global Cancer Minimal Residual Disease Testing Sales Market Share by Region
8.2 North America
8.2.1 North America Cancer Minimal Residual Disease Testing Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Cancer Minimal Residual Disease Testing Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Cancer Minimal Residual Disease Testing Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Cancer Minimal Residual Disease Testing Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Cancer Minimal Residual Disease Testing Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Adaptive Biotechnologies Corporation
9.1.1 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Basic Information
9.1.2 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Product Overview
9.1.3 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Product Market Performance
9.1.4 Adaptive Biotechnologies Corporation Business Overview
9.1.5 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing SWOT Analysis
9.1.6 Adaptive Biotechnologies Corporation Recent Developments
9.2 ArcherDX, Inc. (Invitae Corporation)
9.2.1 ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Basic Information
9.2.2 ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Product Overview
9.2.3 ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Product Market Performance
9.2.4 ArcherDX, Inc. (Invitae Corporation) Business Overview
9.2.5 ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing SWOT Analysis
9.2.6 ArcherDX, Inc. (Invitae Corporation) Recent Developments
9.3 Asuragen
9.3.1 Asuragen Cancer Minimal Residual Disease Testing Basic Information
9.3.2 Asuragen Cancer Minimal Residual Disease Testing Product Overview
9.3.3 Asuragen Cancer Minimal Residual Disease Testing Product Market Performance
9.3.4 Asuragen Cancer Minimal Residual Disease Testing SWOT Analysis
9.3.5 Asuragen Business Overview
9.3.6 Asuragen Recent Developments
9.4 Arup Laboratories
9.4.1 Arup Laboratories Cancer Minimal Residual Disease Testing Basic Information
9.4.2 Arup Laboratories Cancer Minimal Residual Disease Testing Product Overview
9.4.3 Arup Laboratories Cancer Minimal Residual Disease Testing Product Market Performance
9.4.4 Arup Laboratories Business Overview
9.4.5 Arup Laboratories Recent Developments
9.5 Bio-Rad Laboratories
9.5.1 Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Basic Information
9.5.2 Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Product Overview
9.5.3 Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Product Market Performance
9.5.4 Bio-Rad Laboratories Business Overview
9.5.5 Bio-Rad Laboratories Recent Developments
9.6 Cergentis B.V.
9.6.1 Cergentis B.V. Cancer Minimal Residual Disease Testing Basic Information
9.6.2 Cergentis B.V. Cancer Minimal Residual Disease Testing Product Overview
9.6.3 Cergentis B.V. Cancer Minimal Residual Disease Testing Product Market Performance
9.6.4 Cergentis B.V. Business Overview
9.6.5 Cergentis B.V. Recent Developments
9.7 F. Hoffmann- La Roche Ltd
9.7.1 F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Basic Information
9.7.2 F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Product Overview
9.7.3 F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Product Market Performance
9.7.4 F. Hoffmann- La Roche Ltd Business Overview
9.7.5 F. Hoffmann- La Roche Ltd Recent Developments
9.8 Guardant Health
9.8.1 Guardant Health Cancer Minimal Residual Disease Testing Basic Information
9.8.2 Guardant Health Cancer Minimal Residual Disease Testing Product Overview
9.8.3 Guardant Health Cancer Minimal Residual Disease Testing Product Market Performance
9.8.4 Guardant Health Business Overview
9.8.5 Guardant Health Recent Developments
9.9 ICON plc
9.9.1 ICON plc Cancer Minimal Residual Disease Testing Basic Information
9.9.2 ICON plc Cancer Minimal Residual Disease Testing Product Overview
9.9.3 ICON plc Cancer Minimal Residual Disease Testing Product Market Performance
9.9.4 ICON plc Business Overview
9.9.5 ICON plc Recent Developments
9.10 Invivoscribe
9.10.1 Invivoscribe Cancer Minimal Residual Disease Testing Basic Information
9.10.2 Invivoscribe Cancer Minimal Residual Disease Testing Product Overview
9.10.3 Invivoscribe Cancer Minimal Residual Disease Testing Product Market Performance
9.10.4 Invivoscribe Business Overview
9.10.5 Invivoscribe Recent Developments
9.11 Laboratory Corporation of America Holdings
9.11.1 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Basic Information
9.11.2 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Product Overview
9.11.3 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Product Market Performance
9.11.4 Laboratory Corporation of America Holdings Business Overview
9.11.5 Laboratory Corporation of America Holdings Recent Developments
9.12 Mission Bio
9.12.1 Mission Bio Cancer Minimal Residual Disease Testing Basic Information
9.12.2 Mission Bio Cancer Minimal Residual Disease Testing Product Overview
9.12.3 Mission Bio Cancer Minimal Residual Disease Testing Product Market Performance
9.12.4 Mission Bio Business Overview
9.12.5 Mission Bio Recent Developments
9.13 Natera, Inc.
9.13.1 Natera, Inc. Cancer Minimal Residual Disease Testing Basic Information
9.13.2 Natera, Inc. Cancer Minimal Residual Disease Testing Product Overview
9.13.3 Natera, Inc. Cancer Minimal Residual Disease Testing Product Market Performance
9.13.4 Natera, Inc. Business Overview
9.13.5 Natera, Inc. Recent Developments
9.14 NeoGenomics Laboratories
9.14.1 NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Basic Information
9.14.2 NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Product Overview
9.14.3 NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Product Market Performance
9.14.4 NeoGenomics Laboratories Business Overview
9.14.5 NeoGenomics Laboratories Recent Developments
9.15 Opko Health
9.15.1 Opko Health Cancer Minimal Residual Disease Testing Basic Information
9.15.2 Opko Health Cancer Minimal Residual Disease Testing Product Overview
9.15.3 Opko Health Cancer Minimal Residual Disease Testing Product Market Performance
9.15.4 Opko Health Business Overview
9.15.5 Opko Health Recent Developments
9.16 Quest Diagnostics Incorporated
9.16.1 Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Basic Information
9.16.2 Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Product Overview
9.16.3 Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Product Market Performance
9.16.4 Quest Diagnostics Incorporated Business Overview
9.16.5 Quest Diagnostics Incorporated Recent Developments
9.17 Sysmex Corporation
9.17.1 Sysmex Corporation Cancer Minimal Residual Disease Testing Basic Information
9.17.2 Sysmex Corporation Cancer Minimal Residual Disease Testing Product Overview
9.17.3 Sysmex Corporation Cancer Minimal Residual Disease Testing Product Market Performance
9.17.4 Sysmex Corporation Business Overview
9.17.5 Sysmex Corporation Recent Developments
9.18 Genetron Health
9.18.1 Genetron Health Cancer Minimal Residual Disease Testing Basic Information
9.18.2 Genetron Health Cancer Minimal Residual Disease Testing Product Overview
9.18.3 Genetron Health Cancer Minimal Residual Disease Testing Product Market Performance
9.18.4 Genetron Health Business Overview
9.18.5 Genetron Health Recent Developments
10 CANCER MINIMAL RESIDUAL DISEASE TESTING MARKET FORECAST BY REGION
10.1 Global Cancer Minimal Residual Disease Testing Market Size Forecast
10.2 Global Cancer Minimal Residual Disease Testing Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Cancer Minimal Residual Disease Testing Market Size Forecast by Country
10.2.3 Asia Pacific Cancer Minimal Residual Disease Testing Market Size Forecast by Region
10.2.4 South America Cancer Minimal Residual Disease Testing Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Cancer Minimal Residual Disease Testing by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Cancer Minimal Residual Disease Testing Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Cancer Minimal Residual Disease Testing by Type (2025-2030)
11.1.2 Global Cancer Minimal Residual Disease Testing Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Cancer Minimal Residual Disease Testing by Type (2025-2030)
11.2 Global Cancer Minimal Residual Disease Testing Market Forecast by Application (2025-2030)
11.2.1 Global Cancer Minimal Residual Disease Testing Sales (K Units) Forecast by Application
11.2.2 Global Cancer Minimal Residual Disease Testing Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Cancer Minimal Residual Disease Testing Market Size Comparison by Region (M USD)
Table 5. Global Cancer Minimal Residual Disease Testing Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Cancer Minimal Residual Disease Testing Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Cancer Minimal Residual Disease Testing Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Cancer Minimal Residual Disease Testing Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Minimal Residual Disease Testing as of 2022)
Table 10. Global Market Cancer Minimal Residual Disease Testing Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Cancer Minimal Residual Disease Testing Sales Sites and Area Served
Table 12. Manufacturers Cancer Minimal Residual Disease Testing Product Type
Table 13. Global Cancer Minimal Residual Disease Testing Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Cancer Minimal Residual Disease Testing
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Cancer Minimal Residual Disease Testing Market Challenges
Table 22. Global Cancer Minimal Residual Disease Testing Sales by Type (K Units)
Table 23. Global Cancer Minimal Residual Disease Testing Market Size by Type (M USD)
Table 24. Global Cancer Minimal Residual Disease Testing Sales (K Units) by Type (2019-2024)
Table 25. Global Cancer Minimal Residual Disease Testing Sales Market Share by Type (2019-2024)
Table 26. Global Cancer Minimal Residual Disease Testing Market Size (M USD) by Type (2019-2024)
Table 27. Global Cancer Minimal Residual Disease Testing Market Size Share by Type (2019-2024)
Table 28. Global Cancer Minimal Residual Disease Testing Price (USD/Unit) by Type (2019-2024)
Table 29. Global Cancer Minimal Residual Disease Testing Sales (K Units) by Application
Table 30. Global Cancer Minimal Residual Disease Testing Market Size by Application
Table 31. Global Cancer Minimal Residual Disease Testing Sales by Application (2019-2024) & (K Units)
Table 32. Global Cancer Minimal Residual Disease Testing Sales Market Share by Application (2019-2024)
Table 33. Global Cancer Minimal Residual Disease Testing Sales by Application (2019-2024) & (M USD)
Table 34. Global Cancer Minimal Residual Disease Testing Market Share by Application (2019-2024)
Table 35. Global Cancer Minimal Residual Disease Testing Sales Growth Rate by Application (2019-2024)
Table 36. Global Cancer Minimal Residual Disease Testing Sales by Region (2019-2024) & (K Units)
Table 37. Global Cancer Minimal Residual Disease Testing Sales Market Share by Region (2019-2024)
Table 38. North America Cancer Minimal Residual Disease Testing Sales by Country (2019-2024) & (K Units)
Table 39. Europe Cancer Minimal Residual Disease Testing Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Cancer Minimal Residual Disease Testing Sales by Region (2019-2024) & (K Units)
Table 41. South America Cancer Minimal Residual Disease Testing Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Cancer Minimal Residual Disease Testing Sales by Region (2019-2024) & (K Units)
Table 43. Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Basic Information
Table 44. Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Product Overview
Table 45. Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Adaptive Biotechnologies Corporation Business Overview
Table 47. Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing SWOT Analysis
Table 48. Adaptive Biotechnologies Corporation Recent Developments
Table 49. ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Basic Information
Table 50. ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Product Overview
Table 51. ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. ArcherDX, Inc. (Invitae Corporation) Business Overview
Table 53. ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing SWOT Analysis
Table 54. ArcherDX, Inc. (Invitae Corporation) Recent Developments
Table 55. Asuragen Cancer Minimal Residual Disease Testing Basic Information
Table 56. Asuragen Cancer Minimal Residual Disease Testing Product Overview
Table 57. Asuragen Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Asuragen Cancer Minimal Residual Disease Testing SWOT Analysis
Table 59. Asuragen Business Overview
Table 60. Asuragen Recent Developments
Table 61. Arup Laboratories Cancer Minimal Residual Disease Testing Basic Information
Table 62. Arup Laboratories Cancer Minimal Residual Disease Testing Product Overview
Table 63. Arup Laboratories Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Arup Laboratories Business Overview
Table 65. Arup Laboratories Recent Developments
Table 66. Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Basic Information
Table 67. Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Product Overview
Table 68. Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Bio-Rad Laboratories Business Overview
Table 70. Bio-Rad Laboratories Recent Developments
Table 71. Cergentis B.V. Cancer Minimal Residual Disease Testing Basic Information
Table 72. Cergentis B.V. Cancer Minimal Residual Disease Testing Product Overview
Table 73. Cergentis B.V. Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Cergentis B.V. Business Overview
Table 75. Cergentis B.V. Recent Developments
Table 76. F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Basic Information
Table 77. F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Product Overview
Table 78. F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. F. Hoffmann- La Roche Ltd Business Overview
Table 80. F. Hoffmann- La Roche Ltd Recent Developments
Table 81. Guardant Health Cancer Minimal Residual Disease Testing Basic Information
Table 82. Guardant Health Cancer Minimal Residual Disease Testing Product Overview
Table 83. Guardant Health Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Guardant Health Business Overview
Table 85. Guardant Health Recent Developments
Table 86. ICON plc Cancer Minimal Residual Disease Testing Basic Information
Table 87. ICON plc Cancer Minimal Residual Disease Testing Product Overview
Table 88. ICON plc Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. ICON plc Business Overview
Table 90. ICON plc Recent Developments
Table 91. Invivoscribe Cancer Minimal Residual Disease Testing Basic Information
Table 92. Invivoscribe Cancer Minimal Residual Disease Testing Product Overview
Table 93. Invivoscribe Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Invivoscribe Business Overview
Table 95. Invivoscribe Recent Developments
Table 96. Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Basic Information
Table 97. Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Product Overview
Table 98. Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Laboratory Corporation of America Holdings Business Overview
Table 100. Laboratory Corporation of America Holdings Recent Developments
Table 101. Mission Bio Cancer Minimal Residual Disease Testing Basic Information
Table 102. Mission Bio Cancer Minimal Residual Disease Testing Product Overview
Table 103. Mission Bio Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Mission Bio Business Overview
Table 105. Mission Bio Recent Developments
Table 106. Natera, Inc. Cancer Minimal Residual Disease Testing Basic Information
Table 107. Natera, Inc. Cancer Minimal Residual Disease Testing Product Overview
Table 108. Natera, Inc. Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. Natera, Inc. Business Overview
Table 110. Natera, Inc. Recent Developments
Table 111. NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Basic Information
Table 112. NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Product Overview
Table 113. NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. NeoGenomics Laboratories Business Overview
Table 115. NeoGenomics Laboratories Recent Developments
Table 116. Opko Health Cancer Minimal Residual Disease Testing Basic Information
Table 117. Opko Health Cancer Minimal Residual Disease Testing Product Overview
Table 118. Opko Health Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. Opko Health Business Overview
Table 120. Opko Health Recent Developments
Table 121. Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Basic Information
Table 122. Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Product Overview
Table 123. Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 124. Quest Diagnostics Incorporated Business Overview
Table 125. Quest Diagnostics Incorporated Recent Developments
Table 126. Sysmex Corporation Cancer Minimal Residual Disease Testing Basic Information
Table 127. Sysmex Corporation Cancer Minimal Residual Disease Testing Product Overview
Table 128. Sysmex Corporation Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 129. Sysmex Corporation Business Overview
Table 130. Sysmex Corporation Recent Developments
Table 131. Genetron Health Cancer Minimal Residual Disease Testing Basic Information
Table 132. Genetron Health Cancer Minimal Residual Disease Testing Product Overview
Table 133. Genetron Health Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 134. Genetron Health Business Overview
Table 135. Genetron Health Recent Developments
Table 136. Global Cancer Minimal Residual Disease Testing Sales Forecast by Region (2025-2030) & (K Units)
Table 137. Global Cancer Minimal Residual Disease Testing Market Size Forecast by Region (2025-2030) & (M USD)
Table 138. North America Cancer Minimal Residual Disease Testing Sales Forecast by Country (2025-2030) & (K Units)
Table 139. North America Cancer Minimal Residual Disease Testing Market Size Forecast by Country (2025-2030) & (M USD)
Table 140. Europe Cancer Minimal Residual Disease Testing Sales Forecast by Country (2025-2030) & (K Units)
Table 141. Europe Cancer Minimal Residual Disease Testing Market Size Forecast by Country (2025-2030) & (M USD)
Table 142. Asia Pacific Cancer Minimal Residual Disease Testing Sales Forecast by Region (2025-2030) & (K Units)
Table 143. Asia Pacific Cancer Minimal Residual Disease Testing Market Size Forecast by Region (2025-2030) & (M USD)
Table 144. South America Cancer Minimal Residual Disease Testing Sales Forecast by Country (2025-2030) & (K Units)
Table 145. South America Cancer Minimal Residual Disease Testing Market Size Forecast by Country (2025-2030) & (M USD)
Table 146. Middle East and Africa Cancer Minimal Residual Disease Testing Consumption Forecast by Country (2025-2030) & (Units)
Table 147. Middle East and Africa Cancer Minimal Residual Disease Testing Market Size Forecast by Country (2025-2030) & (M USD)
Table 148. Global Cancer Minimal Residual Disease Testing Sales Forecast by Type (2025-2030) & (K Units)
Table 149. Global Cancer Minimal Residual Disease Testing Market Size Forecast by Type (2025-2030) & (M USD)
Table 150. Global Cancer Minimal Residual Disease Testing Price Forecast by Type (2025-2030) & (USD/Unit)
Table 151. Global Cancer Minimal Residual Disease Testing Sales (K Units) Forecast by Application (2025-2030)
Table 152. Global Cancer Minimal Residual Disease Testing Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Cancer Minimal Residual Disease Testing Market Size Comparison by Region (M USD)
Table 5. Global Cancer Minimal Residual Disease Testing Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Cancer Minimal Residual Disease Testing Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Cancer Minimal Residual Disease Testing Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Cancer Minimal Residual Disease Testing Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Minimal Residual Disease Testing as of 2022)
Table 10. Global Market Cancer Minimal Residual Disease Testing Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Cancer Minimal Residual Disease Testing Sales Sites and Area Served
Table 12. Manufacturers Cancer Minimal Residual Disease Testing Product Type
Table 13. Global Cancer Minimal Residual Disease Testing Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Cancer Minimal Residual Disease Testing
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Cancer Minimal Residual Disease Testing Market Challenges
Table 22. Global Cancer Minimal Residual Disease Testing Sales by Type (K Units)
Table 23. Global Cancer Minimal Residual Disease Testing Market Size by Type (M USD)
Table 24. Global Cancer Minimal Residual Disease Testing Sales (K Units) by Type (2019-2024)
Table 25. Global Cancer Minimal Residual Disease Testing Sales Market Share by Type (2019-2024)
Table 26. Global Cancer Minimal Residual Disease Testing Market Size (M USD) by Type (2019-2024)
Table 27. Global Cancer Minimal Residual Disease Testing Market Size Share by Type (2019-2024)
Table 28. Global Cancer Minimal Residual Disease Testing Price (USD/Unit) by Type (2019-2024)
Table 29. Global Cancer Minimal Residual Disease Testing Sales (K Units) by Application
Table 30. Global Cancer Minimal Residual Disease Testing Market Size by Application
Table 31. Global Cancer Minimal Residual Disease Testing Sales by Application (2019-2024) & (K Units)
Table 32. Global Cancer Minimal Residual Disease Testing Sales Market Share by Application (2019-2024)
Table 33. Global Cancer Minimal Residual Disease Testing Sales by Application (2019-2024) & (M USD)
Table 34. Global Cancer Minimal Residual Disease Testing Market Share by Application (2019-2024)
Table 35. Global Cancer Minimal Residual Disease Testing Sales Growth Rate by Application (2019-2024)
Table 36. Global Cancer Minimal Residual Disease Testing Sales by Region (2019-2024) & (K Units)
Table 37. Global Cancer Minimal Residual Disease Testing Sales Market Share by Region (2019-2024)
Table 38. North America Cancer Minimal Residual Disease Testing Sales by Country (2019-2024) & (K Units)
Table 39. Europe Cancer Minimal Residual Disease Testing Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Cancer Minimal Residual Disease Testing Sales by Region (2019-2024) & (K Units)
Table 41. South America Cancer Minimal Residual Disease Testing Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Cancer Minimal Residual Disease Testing Sales by Region (2019-2024) & (K Units)
Table 43. Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Basic Information
Table 44. Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Product Overview
Table 45. Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Adaptive Biotechnologies Corporation Business Overview
Table 47. Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing SWOT Analysis
Table 48. Adaptive Biotechnologies Corporation Recent Developments
Table 49. ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Basic Information
Table 50. ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Product Overview
Table 51. ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. ArcherDX, Inc. (Invitae Corporation) Business Overview
Table 53. ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing SWOT Analysis
Table 54. ArcherDX, Inc. (Invitae Corporation) Recent Developments
Table 55. Asuragen Cancer Minimal Residual Disease Testing Basic Information
Table 56. Asuragen Cancer Minimal Residual Disease Testing Product Overview
Table 57. Asuragen Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Asuragen Cancer Minimal Residual Disease Testing SWOT Analysis
Table 59. Asuragen Business Overview
Table 60. Asuragen Recent Developments
Table 61. Arup Laboratories Cancer Minimal Residual Disease Testing Basic Information
Table 62. Arup Laboratories Cancer Minimal Residual Disease Testing Product Overview
Table 63. Arup Laboratories Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Arup Laboratories Business Overview
Table 65. Arup Laboratories Recent Developments
Table 66. Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Basic Information
Table 67. Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Product Overview
Table 68. Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Bio-Rad Laboratories Business Overview
Table 70. Bio-Rad Laboratories Recent Developments
Table 71. Cergentis B.V. Cancer Minimal Residual Disease Testing Basic Information
Table 72. Cergentis B.V. Cancer Minimal Residual Disease Testing Product Overview
Table 73. Cergentis B.V. Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Cergentis B.V. Business Overview
Table 75. Cergentis B.V. Recent Developments
Table 76. F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Basic Information
Table 77. F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Product Overview
Table 78. F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. F. Hoffmann- La Roche Ltd Business Overview
Table 80. F. Hoffmann- La Roche Ltd Recent Developments
Table 81. Guardant Health Cancer Minimal Residual Disease Testing Basic Information
Table 82. Guardant Health Cancer Minimal Residual Disease Testing Product Overview
Table 83. Guardant Health Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Guardant Health Business Overview
Table 85. Guardant Health Recent Developments
Table 86. ICON plc Cancer Minimal Residual Disease Testing Basic Information
Table 87. ICON plc Cancer Minimal Residual Disease Testing Product Overview
Table 88. ICON plc Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. ICON plc Business Overview
Table 90. ICON plc Recent Developments
Table 91. Invivoscribe Cancer Minimal Residual Disease Testing Basic Information
Table 92. Invivoscribe Cancer Minimal Residual Disease Testing Product Overview
Table 93. Invivoscribe Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Invivoscribe Business Overview
Table 95. Invivoscribe Recent Developments
Table 96. Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Basic Information
Table 97. Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Product Overview
Table 98. Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Laboratory Corporation of America Holdings Business Overview
Table 100. Laboratory Corporation of America Holdings Recent Developments
Table 101. Mission Bio Cancer Minimal Residual Disease Testing Basic Information
Table 102. Mission Bio Cancer Minimal Residual Disease Testing Product Overview
Table 103. Mission Bio Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Mission Bio Business Overview
Table 105. Mission Bio Recent Developments
Table 106. Natera, Inc. Cancer Minimal Residual Disease Testing Basic Information
Table 107. Natera, Inc. Cancer Minimal Residual Disease Testing Product Overview
Table 108. Natera, Inc. Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. Natera, Inc. Business Overview
Table 110. Natera, Inc. Recent Developments
Table 111. NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Basic Information
Table 112. NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Product Overview
Table 113. NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. NeoGenomics Laboratories Business Overview
Table 115. NeoGenomics Laboratories Recent Developments
Table 116. Opko Health Cancer Minimal Residual Disease Testing Basic Information
Table 117. Opko Health Cancer Minimal Residual Disease Testing Product Overview
Table 118. Opko Health Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. Opko Health Business Overview
Table 120. Opko Health Recent Developments
Table 121. Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Basic Information
Table 122. Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Product Overview
Table 123. Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 124. Quest Diagnostics Incorporated Business Overview
Table 125. Quest Diagnostics Incorporated Recent Developments
Table 126. Sysmex Corporation Cancer Minimal Residual Disease Testing Basic Information
Table 127. Sysmex Corporation Cancer Minimal Residual Disease Testing Product Overview
Table 128. Sysmex Corporation Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 129. Sysmex Corporation Business Overview
Table 130. Sysmex Corporation Recent Developments
Table 131. Genetron Health Cancer Minimal Residual Disease Testing Basic Information
Table 132. Genetron Health Cancer Minimal Residual Disease Testing Product Overview
Table 133. Genetron Health Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 134. Genetron Health Business Overview
Table 135. Genetron Health Recent Developments
Table 136. Global Cancer Minimal Residual Disease Testing Sales Forecast by Region (2025-2030) & (K Units)
Table 137. Global Cancer Minimal Residual Disease Testing Market Size Forecast by Region (2025-2030) & (M USD)
Table 138. North America Cancer Minimal Residual Disease Testing Sales Forecast by Country (2025-2030) & (K Units)
Table 139. North America Cancer Minimal Residual Disease Testing Market Size Forecast by Country (2025-2030) & (M USD)
Table 140. Europe Cancer Minimal Residual Disease Testing Sales Forecast by Country (2025-2030) & (K Units)
Table 141. Europe Cancer Minimal Residual Disease Testing Market Size Forecast by Country (2025-2030) & (M USD)
Table 142. Asia Pacific Cancer Minimal Residual Disease Testing Sales Forecast by Region (2025-2030) & (K Units)
Table 143. Asia Pacific Cancer Minimal Residual Disease Testing Market Size Forecast by Region (2025-2030) & (M USD)
Table 144. South America Cancer Minimal Residual Disease Testing Sales Forecast by Country (2025-2030) & (K Units)
Table 145. South America Cancer Minimal Residual Disease Testing Market Size Forecast by Country (2025-2030) & (M USD)
Table 146. Middle East and Africa Cancer Minimal Residual Disease Testing Consumption Forecast by Country (2025-2030) & (Units)
Table 147. Middle East and Africa Cancer Minimal Residual Disease Testing Market Size Forecast by Country (2025-2030) & (M USD)
Table 148. Global Cancer Minimal Residual Disease Testing Sales Forecast by Type (2025-2030) & (K Units)
Table 149. Global Cancer Minimal Residual Disease Testing Market Size Forecast by Type (2025-2030) & (M USD)
Table 150. Global Cancer Minimal Residual Disease Testing Price Forecast by Type (2025-2030) & (USD/Unit)
Table 151. Global Cancer Minimal Residual Disease Testing Sales (K Units) Forecast by Application (2025-2030)
Table 152. Global Cancer Minimal Residual Disease Testing Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Cancer Minimal Residual Disease Testing
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Cancer Minimal Residual Disease Testing Market Size (M USD), 2019-2030
Figure 5. Global Cancer Minimal Residual Disease Testing Market Size (M USD) (2019-2030)
Figure 6. Global Cancer Minimal Residual Disease Testing Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Cancer Minimal Residual Disease Testing Market Size by Country (M USD)
Figure 11. Cancer Minimal Residual Disease Testing Sales Share by Manufacturers in 2023
Figure 12. Global Cancer Minimal Residual Disease Testing Revenue Share by Manufacturers in 2023
Figure 13. Cancer Minimal Residual Disease Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Cancer Minimal Residual Disease Testing Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Cancer Minimal Residual Disease Testing Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Cancer Minimal Residual Disease Testing Market Share by Type
Figure 18. Sales Market Share of Cancer Minimal Residual Disease Testing by Type (2019-2024)
Figure 19. Sales Market Share of Cancer Minimal Residual Disease Testing by Type in 2023
Figure 20. Market Size Share of Cancer Minimal Residual Disease Testing by Type (2019-2024)
Figure 21. Market Size Market Share of Cancer Minimal Residual Disease Testing by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Cancer Minimal Residual Disease Testing Market Share by Application
Figure 24. Global Cancer Minimal Residual Disease Testing Sales Market Share by Application (2019-2024)
Figure 25. Global Cancer Minimal Residual Disease Testing Sales Market Share by Application in 2023
Figure 26. Global Cancer Minimal Residual Disease Testing Market Share by Application (2019-2024)
Figure 27. Global Cancer Minimal Residual Disease Testing Market Share by Application in 2023
Figure 28. Global Cancer Minimal Residual Disease Testing Sales Growth Rate by Application (2019-2024)
Figure 29. Global Cancer Minimal Residual Disease Testing Sales Market Share by Region (2019-2024)
Figure 30. North America Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Cancer Minimal Residual Disease Testing Sales Market Share by Country in 2023
Figure 32. U.S. Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Cancer Minimal Residual Disease Testing Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Cancer Minimal Residual Disease Testing Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Cancer Minimal Residual Disease Testing Sales Market Share by Country in 2023
Figure 37. Germany Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Cancer Minimal Residual Disease Testing Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Cancer Minimal Residual Disease Testing Sales Market Share by Region in 2023
Figure 44. China Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Cancer Minimal Residual Disease Testing Sales and Growth Rate (K Units)
Figure 50. South America Cancer Minimal Residual Disease Testing Sales Market Share by Country in 2023
Figure 51. Brazil Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Cancer Minimal Residual Disease Testing Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Cancer Minimal Residual Disease Testing Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Cancer Minimal Residual Disease Testing Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Cancer Minimal Residual Disease Testing Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Cancer Minimal Residual Disease Testing Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Cancer Minimal Residual Disease Testing Market Share Forecast by Type (2025-2030)
Figure 65. Global Cancer Minimal Residual Disease Testing Sales Forecast by Application (2025-2030)
Figure 66. Global Cancer Minimal Residual Disease Testing Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of Cancer Minimal Residual Disease Testing
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Cancer Minimal Residual Disease Testing Market Size (M USD), 2019-2030
Figure 5. Global Cancer Minimal Residual Disease Testing Market Size (M USD) (2019-2030)
Figure 6. Global Cancer Minimal Residual Disease Testing Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Cancer Minimal Residual Disease Testing Market Size by Country (M USD)
Figure 11. Cancer Minimal Residual Disease Testing Sales Share by Manufacturers in 2023
Figure 12. Global Cancer Minimal Residual Disease Testing Revenue Share by Manufacturers in 2023
Figure 13. Cancer Minimal Residual Disease Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Cancer Minimal Residual Disease Testing Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Cancer Minimal Residual Disease Testing Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Cancer Minimal Residual Disease Testing Market Share by Type
Figure 18. Sales Market Share of Cancer Minimal Residual Disease Testing by Type (2019-2024)
Figure 19. Sales Market Share of Cancer Minimal Residual Disease Testing by Type in 2023
Figure 20. Market Size Share of Cancer Minimal Residual Disease Testing by Type (2019-2024)
Figure 21. Market Size Market Share of Cancer Minimal Residual Disease Testing by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Cancer Minimal Residual Disease Testing Market Share by Application
Figure 24. Global Cancer Minimal Residual Disease Testing Sales Market Share by Application (2019-2024)
Figure 25. Global Cancer Minimal Residual Disease Testing Sales Market Share by Application in 2023
Figure 26. Global Cancer Minimal Residual Disease Testing Market Share by Application (2019-2024)
Figure 27. Global Cancer Minimal Residual Disease Testing Market Share by Application in 2023
Figure 28. Global Cancer Minimal Residual Disease Testing Sales Growth Rate by Application (2019-2024)
Figure 29. Global Cancer Minimal Residual Disease Testing Sales Market Share by Region (2019-2024)
Figure 30. North America Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Cancer Minimal Residual Disease Testing Sales Market Share by Country in 2023
Figure 32. U.S. Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Cancer Minimal Residual Disease Testing Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Cancer Minimal Residual Disease Testing Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Cancer Minimal Residual Disease Testing Sales Market Share by Country in 2023
Figure 37. Germany Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Cancer Minimal Residual Disease Testing Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Cancer Minimal Residual Disease Testing Sales Market Share by Region in 2023
Figure 44. China Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Cancer Minimal Residual Disease Testing Sales and Growth Rate (K Units)
Figure 50. South America Cancer Minimal Residual Disease Testing Sales Market Share by Country in 2023
Figure 51. Brazil Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Cancer Minimal Residual Disease Testing Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Cancer Minimal Residual Disease Testing Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Cancer Minimal Residual Disease Testing Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Cancer Minimal Residual Disease Testing Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Cancer Minimal Residual Disease Testing Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Cancer Minimal Residual Disease Testing Market Share Forecast by Type (2025-2030)
Figure 65. Global Cancer Minimal Residual Disease Testing Sales Forecast by Application (2025-2030)
Figure 66. Global Cancer Minimal Residual Disease Testing Market Share Forecast by Application (2025-2030)
